Clarity Boosts US Production Capacity for Prostate Cancer Imaging Agent

Significant Manufacturing Scale-Up for 64Cu-SAR-bisPSMA

Clarity Pharmaceuticals (ASX:CU6) has taken a critical step toward commercialising its prostate cancer imaging agent, 64Cu-SAR-bisPSMA, by signing a Commercial Manufacturing Agreement with Nucleus RadioPharma. The deal covers production at Nucleus’s Rochester, Minnesota facility, capable of manufacturing around 50,000 patient doses annually, and a planned Spring House, Pennsylvania site set to open in 2028 with capacity for up to 600,000 doses per year. This expansion is designed to provide comprehensive coverage across the US and select international markets including Europe.

Strengthening a Tiered US Supply Network

The agreement complements Clarity’s existing partnerships, including a Master Services Agreement and clinical supply deal with Nucleus from November 2024, as well as copper-64 supply contracts with SpectronRx, Nusano, and Theragenics. This multi-site, multi-partner approach aims to secure a robust and scalable supply chain ahead of 64Cu-SAR-bisPSMA’s anticipated commercial launch following Phase III trials AMPLIFY and CLARIFY and subsequent FDA approval. The company’s strategy reflects a clear understanding of the logistical challenges in radiopharmaceutical distribution, leveraging copper-64’s longer half-life for flexible delivery models.

Clarity’s recent major copper-64 supply deal with Theragenics further underscores this effort to build a geographically diverse manufacturing footprint in the US, critical for meeting anticipated demand in prostate cancer diagnostics.

Clinical Promise Meets Manufacturing Readiness

The manufacturing agreement arrives as Clarity’s 64Cu-SAR-bisPSMA shows promising clinical results, with data indicating superior detection of prostate cancer lesions compared to current PSMA PET standards. Nucleus RadioPharma’s leadership emphasised the potential for earlier and more accurate cancer detection to improve patient outcomes, aligning with Clarity’s mission. The deal also highlights Nucleus’s growing role as a key CDMO in radiopharmaceuticals, backed by notable institutions including Mayo Clinic and AstraZeneca.

Clarity’s Executive Chairperson, Alan Taylor, highlighted the strategic importance of securing large-scale manufacturing capacity to support a commercial rollout from day one, aiming to serve not only existing PSMA PET markets but also to expand patient access based on the enhanced performance of their product. The company’s layered supply network is designed to be secure, abundant, and responsive to market needs.

Regulatory and Commercial Milestones Ahead

While 64Cu-SAR-bisPSMA and its therapeutic counterpart 67Cu-SAR-bisPSMA remain unregistered and subject to regulatory approval, the manufacturing agreements signal Clarity’s confidence in progressing toward market authorisation. The Phase III AMPLIFY and CLARIFY trials are pivotal steps, with the former having recently completed enrolment and the latter ongoing. The company’s ability to scale manufacturing ahead of FDA approval is a notable move in reducing time-to-market if regulatory hurdles are cleared.

Investors should note that while the expanded manufacturing capacity is a positive development, commercial success will depend on trial outcomes and regulatory decisions. The evolving US supply chain landscape for radiopharmaceuticals remains competitive and complex, with Clarity positioning itself as a strong contender.